Towards a "pharma power"

It is against this background that the curtain of China's pharmaceutical reform opened in 2015, in recent years, China has been launching independent research and development of new anti-cancer drugs, and has been internationally recognizedRecently, the U.SFood and Drug Administration approved the Chinese new drug Zebutini for the treatment of set cell lymphoma, which is the first chinese biopharmaceutical company independentresearch and development, the U.SDrug Administration approved the listing of anti-cancer drugs, is China's biopharmaceutical industry and clinical tumor research a milestoneit is understood that Zebutini for oral medicine, do not have to be hospitalized, can turn cancer into a chronic disease like high blood pressure, diabetes, so that patients live normally in the long termWhy is this medicine so cow? It pours a lot of wisdom and effort stoking the researchersThere is a set of figures: it takes an average of $2 billion to develop a new cancer drug, which takes 12 to 15 yearsIt's so hard, the research and development team has to go head-to-head because they have a firm initial and determination to let domestic cancer patients use the world's best domestic new drugsin order to achieve this goal, 41-year-old elected to the National Academy of Sciences, Wang Xiaodong resolutely chose to return home, the establishment of Baiji Shenzhou Biotech Co., Ltd., many scholars in the field of scientific research has made achievements since the wage reduction to join, down-to-earth scientific research, quietly work, nearly 8 years of efforts finally blossomedZebitini's emergence is the first step for "Chinese Pharmaceuticals" to stand up and go outWang Xiaodong's team is not an isolated caseIn recent years, China's pharmaceutical industry to accelerate the transformation and upgrading, especially in the pharmaceutical reform, medical reform and other policies, driven by the rise of the pharmaceutical industry innovation wave, a large number of scientists came to China to invest in new drug research and development, for the pharmaceutical industry from imitation to innovation, from the mainland to the world, injected great vitalitymade a good start to the companyAfter the U.SDrug Enforcement Administration approved the listing, Zebutini strode overseas, Chinese scientists, Chinese enterprises really achieved the international "landing" and achieved a new drug "zero breakthrough" out to seaThis will inspire more pharmaceutical companies to continue to invest in innovation, catch up, master more key core technologies, and contribute more "China programs" to cancer patients worldwideIt will also push China towards the strategic goal of a "pharmaceutical power" and become a more active participant, builder and contributor to global health governance.